Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

venetoclax 104Azacitidine 88Cytarabine 74Specimen Handling 49fludarabine 46Biopsy 35Daunorubicin 30Cyclophosphamide 30Injections 28Decitabine 28fludarabine phosphate 26Idarubicin 25Busulfan 22Granulocyte Colony-Stimulating Factor 20Whole-Body Irradiation 19Mycophenolic Acid 19Tacrolimus 18decitabine and cedazuridine drug combination 17Melphalan 17CPX-351 17Stem Cell Transplantation 15gilteritinib 14ivosidenib 13Mitoxantrone 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 11Filgrastim 11Etoposide 11Cladribine 11Thiotepa 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Cytochrome P-450 CYP2C9 × 90 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡